Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Lpath, Inc.
Cash is available for start-up, growth-stage and public companies through Texas Medical Center’s newly doubled venture fund, a pandemic preparedness initiative and new VC funds. In recent financings, Nutcracker closed a $167m series C round and 2Seventy raised $170m in a private placement.
Not all of the key medtech deals of 2016 were blockbusters. Herein are some of the more interesting smaller deals of the year.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2016.
Obesity device firm Apollo Endosurgery and drug firm LPath Inc. have announced plans to merge in an agreement that is intended to transition the privately held Apollo into a NASDAQ-listed company.
- In Vitro Diagnostics
- Drug Discovery Tools
- Other Names / Subsidiaries
- Lpath Therapeutics Inc.
- Neighborhood Connections, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.